By Chris Wack


AC Immune SA said it saw positive new interim Phase 1b/2a data on ACI-35.030, a first-in-class anti-phosphorylated-Tau vaccine candidate being developed in partnership with Janssen Pharmaceuticals Inc.

The company said ACI-35.030 is the first Alzheimer's disease vaccine candidate designed to generate antibodies targeting pathological pTau in the brain.

AC Immune said results from the trial show that ACI-35.030 treatment led to the strong induction of antibodies specific for pathological forms of Tau such as pTau and its aggregated form, enriched paired helical filaments. Anti-pTau IgG titers increased by two orders of magnitude from baseline already two weeks after the first injection of the mid-dose of ACI-35.030.

Interim safety data further support ACI-35.030's favorable safety and tolerability profile, with no clinically relevant safety concerns observed to date.

As previously reported, the ongoing Phase 1b/2a study has been expanded to include a total of 24 Alzheimer's disease participants in the mid-dose sub-cohort. This expansion was designed to support the advancement of ACI-35.030 into late-stage development.

AC Immune shares were up 11% to $6.70 in premarket trading.


Write to Chris Wack at


(END) Dow Jones Newswires

November 12, 2021 09:29 ET (14:29 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more AC Immune Charts.
Historical Stock Chart
From May 2021 to May 2022 Click Here for more AC Immune Charts.